TRAF1 anticorps (AA 73-219)

N° du produit ABIN6938673

L’anticorps Souris Monoclonal anti-TRAF1 a été validé pour IHC et IHC (f). Il convient pour détecter TRAF1 dans des échantillons de Humain.

Aperçu rapide pour TRAF1 anticorps (AA 73-219) (ABIN6938673)

Antigène: TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TRAF1 est non-conjugé

Application: Immunohistochemistry (IHC), Immunohistochemistry (Formalin-fixed Sections) (IHC (f))

Clone: TRAF1-3298

Détail du produit anti-TRAF1 anticorps

Épitope: AA 73-219

Specificité: This MAb recognizes a protein of 52 kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30 % of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84 %) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7 %). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.

Réactivité croisée (Details): Human.

Purification: 1.0mg/ml of Ab purified from Bioreactor by Protein A/G.

Immunogène: Recombinant fragment of human TRAF1 protein (around aa 73-219) (exact sequence is proprietary)

Isotype: IgG2b kappa

Information d'application

Indications d'application:

Known_Application: Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT) ,(Staining of formalin-fixed tissues requires heating tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes), Optimal dilution for a specific application should be determined.

Positive_Control: HeLa or 293T cells. Hodgkin s Lymphoma (IHC).

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Buffer: Prepared in 10 mM PBS, WITHOUT BSA and Azide.

Agent conservateur: Azide free

Stock: -20 °C,-80 °C

Stockage commentaire: Antibody without azide store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous.

Date de péremption: 24 months

Détails sur TRAF1

Antigène: TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

Autre désignation: TRAF1

Sujet: EBI6, EBV induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1, TRAF1,TRAF1 (TNFR-Associated Factor 1) (Lymphomatoid Papulosis Marker)
Cellular localisation: Cytoplasmic

Poids moléculaire: 52kDa

ID gène: 7185, 531251

UniProt: Q13077

Pathways: Signalisation NF-kappaB, Apoptose, Cell-Cell Junction Organization, Asymmetric Protein Localization